| |
Patients |
|
| |
Total n=16 |
IAR n=17 |
LAR n=21 |
DLAR n=8 |
DYAR n=11 |
DDYAR n=5 |
NAR n=35 |
Control subjects n=15 |
| Group I/II |
47/15 |
14/3 |
13/8 |
5/3 |
8/3 |
3/2 |
19/16 |
|
| Age (years) |
29 ± 5 |
24 ± 3 |
30 ± 4 |
35 ± 6 |
26 ± 4 |
25 ± 2 |
28 ± 7 |
31 ± 4 |
| Gender (M/F) |
29/33 |
8/9 |
9/12 |
4/4 |
6/5 |
2/3 |
16/10 |
7/8 |
| Disease history (years) |
5.1 ± 0.6 |
5.0 ± 1.0 |
4.7 ± 1. |
5.5 ± 1.4 |
5.6 ± 0.9 |
4.8 ± 0.7 |
5.9 ± 1.8 |
4.5 ± 1.2 |
| FEV1 (% predicted) |
96 ± 5 |
94 ± 3 |
98 ± 2 |
95 ± 6 |
97 ± 3 |
93 ± 6 |
95 ± 3 |
97 ± 2 |
| FVC (% predicted) |
99 ± 2 |
98 ± 4 |
100 ± 3 |
98 ± 5 |
103 ± 4 |
99 ± 3 |
104 ± 2 |
98 ± 3 |
| Blood leukocyte count (x 109 /L)● |
8.0 ± 0.78 |
8.3 ± 1.0 |
7.8 ± 0.5 |
6.9 ± 1.0 |
9.1 ± 0.5 |
9.1 ± 0.5 |
8.1 ± 1.3 |
7.9 ± 0.6 |
| Blood eosinophil count (x 106 /L)●● |
355 ± 52 |
389 ± 44 |
334 ± 27 |
392 ± 53 |
257 ± 19 |
288 ± 22 |
263 ± 13 |
413 ± 69 |
| Blood neutrophil count (x 109 /L)●●● |
5.4 ± 0.6 |
4.9 ± 0.8 |
5.6 ± 0.4 |
4.8 ± 1.1 |
5.1 ± 1.0 |
6.9 ± 0.5 |
5.5 ± 0.7 |
5.3 ± 0.8 |
| Bronchial histamine threshold (BHT)□ |
|
|
|
|
|
|
|
|
| ≤2.0 mg/ml |
4 |
2 |
1 |
0 |
1 |
0 |
8 |
2 |
| 4.0 mg/ml |
7 |
1 |
2 |
1 |
1 |
2 |
10 |
6 |
| 8.0 mg/ml |
6 |
2 |
1 |
2 |
0 |
1 |
9 |
5 |
| 16.0 mg/ml |
9 |
3 |
2 |
2 |
1 |
1 |
6 |
1 |
| 32.0 mg/ml |
14 |
3 |
3 |
3 |
4 |
1 |
2 |
1 |
| >32.0 mg/ml |
22 |
6 |
12 |
0 |
4 |
0 |
0 |
0 |
Values=mean ± SD; ●=normal value=4.0-10.0×109/L; ●●=normal value=<300×106/L; ●●● normal value=2.0-7.2×109/L; □=normal value ≥ 32.0 mg/mL [76-79,81,82] |
